Počet záznamov: 1
ranibizumab
SYS d000069579 LBL 00000nz--a2200181n--4500 005 20250606221751.2 008 160101|||anznnbabn-----------|-a|a------ 040 $b slo $a BA006 $d BA006 $d BA006 065 $a D12.776.124.486.485.114.224.060.868 065 $a D12.776.124.790.651.114.224.060.868 065 $a D12.776.377.715.548.114.224.200.868 066 $a 01 $c 03 150 $a ranibizumab $x AD $x AE $x AN $x BI $x BL $x CF $x CH $x CL $x DE $x EC $x GE $x HI $x IM $x IP $x ME $x PD $x PH $x PK $x PO $x RE $x TO $x TU $x UL $x UR $2 slo 450 $w v $a RhuFab V2 $2 slo 550 $7 sllk_us_auth*d020533 $Y Angiogenesis Inhibitors $w P $a inhibítory angiogenézy 550 $7 sllk_us_auth*d042461 $Y Vascular Endothelial Growth Factor A $w p $a faktor A, rastový endotelový vaskulárny 665 $a 2016 (2005) $2 eng 680 9-
$i A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION. $2 eng 750 -2
$a Ranibizumab $2 eng 980 $x M
Počet záznamov: 1